Group 1 - The company reported a revenue of 106 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 22.5% [1] - Gross profit reached 65.12 million RMB, showing a year-on-year increase of 48.86% [1] - Research and development expenses amounted to 92.04 million RMB, indicating a focus on innovation and product development [1] Group 2 - The leading product, Benaoda®, has made continuous progress in commercialization [2] - The company completed patient enrollment for a clinical trial of Benaoda® as a second-line treatment for relapsed or refractory large B-cell lymphoma (LBCL) patients [2] - The National Medical Products Administration granted Benaoda® "Breakthrough Therapy Designation" in January 2025, and a supplemental new drug application (sNDA) was submitted in May 2025 [2] - The company developed its own platform technology and successfully produced lentiviral vectors for Benaoda®, reducing product costs [2] - Clinical studies have shown comparable results to existing lentiviral vectors, and patient enrollment for the investigational new drug application (IND) has been completed [2] - Significant progress has been made in developing innovative products with global commercialization potential [2]
药明巨诺-B(02126)发布中期业绩 毛利6511.7万元 同比增加48.86%